^
Association details:
| Biomarker: | SLC22A1 1222AG |
|---|---|
| Cancer: | Chronic Myeloid Leukemia |
| Drug: | imatinib (YD312) (c-KIT inhibitor, SCF signal transduction pathway inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Association of SLC22A1,SLCO1B3 Drug Transporter Polymorphisms and Smoking with Disease Risk and Cytogenetic Response to Imatinib in Patients with Chronic Myeloid Leukemia
Published date:
06/15/2021
Excerpt:
To determine whether polymorphisms of SLC22A1 and SLCO1B3 genes could predict imatinib (IM) response and chronic myeloid leukemia (CML) risk...IM resistance for SLC22A1c.1222AG (P = .03; OR = 2.2), SLCO1B3c.334TT/TG genotypes (P = .007; OR = 4.37) and 334T allele (P = .03; OR = 2.86).
DOI:
10.1093/labmed/lmab023
